OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial ...
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...
Xenetic: PeriNess in XBIO-015 study to treat osteosarcoma and Ewing sarcoma
Biosciences, announced that its collaboration partner, PeriNess has entered into a Clinical Study Agreement to support an ...
Xenetic partner PeriNess enters clinical study agreement for XBIO-015
Biosciences’ collaboration partner, PeriNess has entered into a Clinical Study Agreement to support an exploratory clinical ...